IMC Chicago LLC Purchases 2,335 Shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS)
IMC Chicago LLC Purchases 2,335 Shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.IMC Chicago LLC increased its position in shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Rating) by 12.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,003 shares of the company's stock after acquiring an additional 2,335 shares during the period. IMC Chicago LLC owned about 5.25% of ProShares UltraShort Nasdaq Biotechnology worth $566,000 as of its most recent filing with the Securities and Exchange Commission.
IMC芝加哥有限责任公司根据其最近提交给美国证券交易委员会的文件，在第二季度将其在ProShares UltraShort纳斯达克生物科技公司(纳斯达克：BIS-GET评级)的股票头寸增加了12.5%。该机构投资者持有该公司21,003股股票，在此期间又购买了2,335股。据最近提交给美国证券交易委员会的文件显示，IMC Chicago LLC持有ProShares UltraShort纳斯达克约5.25%的股份，价值566,000美元。
Separately, UBS Group AG grew its stake in shares of ProShares UltraShort Nasdaq Biotechnology by 54.7% in the first quarter. UBS Group AG now owns 1,371 shares of the company's stock worth $33,000 after purchasing an additional 485 shares during the last quarter.
另外，瑞银集团(UBS Group AG)今年第一季度增持了ProShares UltraShort纳斯达克生物科技股份54.7%。瑞银集团(UBS Group AG)在上个季度增持了485股瑞银股票后，目前持有1,371股该公司股票，价值33,000美元。
ProShares UltraShort Nasdaq Biotechnology Stock Performance
ProShares超短纳斯达克生物科技股表现
ProShares UltraShort Nasdaq Biotechnology stock opened at $21.07 on Friday. ProShares UltraShort Nasdaq Biotechnology has a 52-week low of $18.37 and a 52-week high of $35.64. The firm has a 50 day moving average price of $23.69 and a two-hundred day moving average price of $25.55.
ProShares UltraShort纳斯达克生物科技股周五开盘报21.07美元。ProShares UltraShort纳斯达克生物科技的52周低点为18.37美元，52周高点为35.64美元。该公司的50日移动均线价格为23.69美元，200日移动均线价格为25.55美元。
ProShares UltraShort Nasdaq Biotechnology Profile
ProShares UltraShort纳斯达克生物技术简介
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.
ProShares超纳斯达克生物科技(基金)只寻求一天的投资结果，不寻求较长时期的投资结果。基金寻求扣除费用和费用前的每日投资结果，相当于该指数每日业绩的两倍(200%)。超过一个交易日的基金回报将是这段时间内每一天的回报的复合结果，这很可能与同期纳斯达克生物技术指数(该指数)的回报两倍(200%)不同。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on ProShares UltraShort Nasdaq Biotechnology (BIS)
- MarketBeat: Week in Review 10/31-11/4
- Is Hershey's a Sweet Stock to Buy After a Post-Earnings Dip?
- Datadog Doesn't Belong In The Doghouse
- Mixed Results Actually Bring More Optimism than Risk for AMD
- Nikola Shares Fall Even As EV Maker Beats Q3 Expectations
- 免费获取StockNews.com关于ProShares UltraShort纳斯达克生物技术的研究报告
- MarketBeat：回顾中的一周10/31-11/4
- 好时是一只在盈利后下跌后买入的甜蜜股票吗？
- Datadog不属于狗舍
- 喜忧参半的结果实际上给AMD带来的乐观情绪多于风险
- 尼古拉股价下跌，尽管电动汽车制造商第三季度业绩好于预期
Receive News & Ratings for ProShares UltraShort Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares UltraShort Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
获得ProShares UltraShort纳斯达克生物科技日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ProShares UltraShort纳斯达克生物技术和相关公司的最新新闻和分析师评级的每日摘要。